Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients
A single-center analysis

Tae Hoon Roh, MD[a,b], Hun Ho Park, MD[c,h], Seok-Gu Kang, MD, PhD[c,h,i], Ju Hyung Moon, MD[c,h], Eui Hyun Kim, MD, PhD[c,h,i], Chang-Ki Hong, MD, PhD[c,h], Sung Soo Ahn, MD, PhD[d,h], Hye Jin Choi, MD, PhD[e,h], Jaeho Cho, MD, PhD[f,h], Se Hoon Kim, MD, PhD[g,h], Seung Koo Lee, MD, PhD[d,h], Dong Seok Kim, MD, PhD[c,i], Sun Ho Kim, MD, PhD[c,h,i], Chang-Ok Suh, MD, PhD[f,h], Kyu Sung Lee, MD, PhD[c,h,i], Jong Hee Chang, MD, PhD[c,h,*]

Abstract

The present study analyzed outcomes of surgery followed by concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) at a single institution. Outcomes were retrospectively reviewed in 252 consecutive patients with newly diagnosed GBM who underwent surgery followed by CCRT with TMZ at the authors' institution between 2005 and 2013. At initial operation, 126 (50.0%), 55 (21.8%), 45 (17.9%), and 26 (10.3%) patients underwent gross total resection (GTR), subtotal resection, partial resection (PR), and biopsy, respectively. Their median overall survival (OS) was 20.8 months (95% confidence interval [CI] 17.7–23.9 months) and their median progression-free survival was 12.7 months (95% CI 11.2–14.2 months). The O^6-methylguanine-DNA methyltransferase (MGMT) promoter was methylated in 78 (34.1%) of the 229 patients assayed, and an isocitrate dehydrogenase 1 mutation was detected in 7 (6.6%) of the 106 patients analyzed. Univariate analyses showed that patient age, involvement of eloquent areas, involvement of the subventricular zone, presence of leptomeningeal seeding, Karnofsky Performance Status, extent of resection (EOR), MGMT promoter methylation, and presence of an oligodendroglioma component were prognostic of OS. Multivariate analysis showed that age, involvement of eloquent areas, presence of leptomeningeal seeding, EOR, and MGMT promoter methylation were significantly predictive of survival. OS in patients with GBM who undergo surgery followed by CCRT with TMZ is enhanced by complete resection. Other factors significantly prognostic of OS include that age, involvement of eloquent areas, presence of leptomeningeal seeding, and MGMT promoter methylation.

Abbreviations: CCRT = concomitant chemoradiotherapy, EOR = extent of resection, GBM = glioblastoma, GTR = gross total resection, IDH = isocitrate dehydrogenase, KPS = Karnofsky performance status, MGMT = O^6-methylguanine-DNA methyltransferase, MRI = magnetic resonance imaging, OS = overall survival, PFS = progression-free survival, STR = subtotal resection, SVZ = subventricular zone, TMZ = temozolomide.

Keywords: chemoradiotherapy, DNA methylation, glioblastoma, survival analysis, temozolomide

[a] Yonsei University Graduate School, Seoul, [b] Department of Neurosurgery, Ajou University Hospital, Ajou University School of Medicine, Suwon, [c] Department of Neurosurgery, [d] Department of Radiology, [e] Department of Medical Oncology, [f] Department of Radiation Oncology, [g] Department of Pathology, Yonsei University College of Medicine, [h] Brain Tumor Center, Severance Hospital, Yonsei University Health System, [i] Brain Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.

* Correspondence: Jong Hee Chang, Department of Neurosurgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea (e-mail: changjh@yuhs.ac)

1. Introduction

Glioblastoma (GBM) is the most malignant and common primary brain tumor in adults. Standard therapy of patients with newly diagnosed GBM includes resection followed by concomitant chemoradiotherapy (CCRT) and adjuvant temozolomide (TMZ).[1] Despite treatment, however, the median overall survival (OS) of patients with GBM is only 14.6 to 21.1 months.[2,3]

Characteristics prognostic of survival in patients with GBM include clinical factors such as age, performance score, and extent of resection (EOR), along with factors associated with tumor location, such as invasion of eloquent areas or the subventricular zone (SVZ) and coexistence of leptomeningeal seeding.[4–6] Survival rate is strongly dependent on treatment modality; adjuvant chemoradiotherapy with TMZ is considered standard because it significantly increases patient survival rate. Furthermore, advances in surgical techniques and technology have been reported to improve survival.[7,8]

Molecular prognostic factors in GBM include mutations in the genes encoding isocitrate dehydrogenase (IDH) 1/2 and methylation of the O^6-methylguanine-DNA methyltransferase

(MGMT) promoter.[9,10] MGMT promoter methylation has also been found to predict response to TMZ-based chemotherapy.[9] A meta-analysis published in 2014, which investigated the prognostic value of MGMT promoter methylation in different races, reported that, in Asians, MGMT promoter methylation was not related to OS by univariate analysis or to progression-free survival (PFS) by multivariate analysis.[11] However, this meta-analysis included only 6 studies in Asians, compared with 46 in Caucasians, as only a few studies have reported molecular information on GBM in Asian patients.[12]

To assess the survival benefits of standard treatment, this study analyzed 252 consecutive GBM patients who underwent surgery followed by standard chemoradiotherapy (CCRT) plus TMZ at a single institution. The associations of MGMT promoter methylation and IDH1 mutation status with survival were also investigated.

2. Materials and methods

2.1. Patient recruitment

The present retrospective study was approved by our institutional review board, which waived the requirement for patient informed consent due to the retrospective nature of this study (2015-2474-001). All patients coded as having GBM histology at Yonsei University Severance Hospital from 2005 to 2013 were screened. Subjects were included if they had been histologically diagnosed with GBM according to the World Health Organization (WHO) classification of central nervous system tumors,[13] as confirmed by 2 pathologists (SHK and JC). Patients having GBM with oligodendroglioma component (GBMO) and giant cell GBM (GCGBM) were also included. Patients were excluded if preoperative or follow-up images were unavailable, if they were aged <18 years, if they had coexisting malignancy or gliosarcoma. Patients and their guardians were informed of treatment options before surgery and when pathological diagnosis was obtained after surgery. The patients who agreed to start standard CCRT with TMZ were included in the analysis. All patients were followed up until death or the time of analysis (August 2016).

2.2. Treatment protocols

Tumors were removed following the protocol of maximal safe resection, except for patients who underwent biopsy. Most patients underwent navigation-guided surgery, using intraoperative magnetic resonance imaging (MRI) in 39 patients and 5-aminolevulinic acid in 74. Diffusion tensor image tractography was used for navigation in patients with tumors located adjacent to areas of motor, vision, and language functions to minimize possible damage. Awake craniotomy was performed in 24 patients. Most patients (87%) started CCRT with using Stupp regimen (daily 75 mg/BSA of TMZ plus 60 Gy of radiotherapy fractionated 2 Gy/d) within 3 weeks of surgery.[1] Twenty-eight days following the completion of CCRT, TMZ was started; 6 cycles were administered unless adverse event or progression was detected.

In cases of recurrence, reoperation was considered a priority, when the tumor was resectable. Maximal safe resection was attempted using the method used for initial surgery. Repeat radiotherapy was again recommended after surgery. If the recurrent tumor was considered unresectable, due to deep location, involvement of eloquent areas, or small size, gamma-knife radiosurgery was recommended. Adjuvant TMZ adminis-

tration was also considered following repeat radiotherapy. If the tumor rerecurred, bevacizumab was considered as salvage treatment.

2.3. Image analysis

All patients underwent pre- and postoperative MRI, with images stored in a picture archiving and communication system. Images were assessed and reviewed by 2 experienced radiologists. Parameters evaluated preoperatively included tumor size (maximal diameter of enhancing lesion), primary lesion location, relationship to eloquent areas, SVZ involvement, and leptomeningeal seeding. The size of the tumor was classified using cutoff value of 3.4 cm, chosen by Contal and O'Quigley method.[14]

The EOR was determined by early (<48 hours) postoperative MRI. Gross total resection (GTR) was defined as the absence of a residual lesion, based on T1-weighted contrast enhancement images. When the tumor was left in the surgical field, the tumor was considered to have undergone a STR even if no tumor was seen in the postoperative MRI findings. Subtotal resection (STR) was defined as the presence of a residual tumor but EOR was >90%. Partial resection (PR) was defined as the presence of >10% of tumors (EOR <90%). In the case of a discrepancy, 3 observers (THR, MCO, and JHC) simultaneously reviewed the images to achieve consensus.

Follow-up MRIs were performed before the start of the first and fourth TMZ cycles and 1 month after the end of the sixth cycle. Patients underwent follow-up MRI every 3 months for the first 2 years, and every 6 or 12 months thereafter. Patients suspected of disease progression, as defined by RANO criteria, underwent immediate MRI.[15]

A transient progressive lesion within 3 months after radiotherapy was considered pseudoprogression. Patients with an apparent newly appearing enhancing mass were assessed by MR spectroscopy, ^{11}C-methionine positron emission tomography, or perfusion MRI to differentiate between radiation necrosis and recurrence.

2.4. Molecular analysis

Genomic DNA was isolated from paraffin-embedded samples of 229 patients. The DNA methylation status of the CpG islands at the MGMT promoter was determined by methylation-specific polymerase chain reaction, as described, with some modifications.[16,17]

Representative tissue sections were assessed by immunohistochemistry, using a Ventana BenchMark XT autostainer (Ventana Medical System, Inc. Tucson, AZ) according to the manufacturer's protocols. Primary antibodies included anti-human IDH1 R132H mouse monoclonal (clone H09L, Dianova, 1:80 dilution) and anti-Ki-67 (clone Mib-1, Dako, 1:150 dilution). Samples showing cytoplasmic expression of IDH1 R132H in glioma cells were classified as positive for mutation, with all others classified as "wild-type." MIB-1 (Ki67) score was defined as the percentage of positive nuclei among 1000 tumor cells, or as many as possible in the case of small specimens.

2.5. Statistical analysis

Survival outcomes were analyzed by the Kaplan–Meier method and compared by the log-rank test. Multivariate Cox proportional hazards models were created to test for associations of factors with PFS and OS. In these models, EOR was dichotomized

as complete (gross total) versus incomplete (subtotal, partial, and biopsy). All statistical tests were 2-sided, and the threshold for statistical significance was $P < .05$. All analyses were performed with SPSS for Windows version 20.0 (SPSS Inc., Chicago, IL) and SAS version 9.2 (SAS Institute Inc., Cary, NC).

3. Results

3.1. Patient characteristics and overall survival

Between January 2005 to December 2013, 313 patients newly diagnosed with pathologically proven GBM were treated at Yonsei University Severance Hospital. Sixty-one patients were excluded, including 11 aged <18 years, 21 who were lost to follow-up, 4 who had a coexisting malignancy, 4 who died of pneumonia before CCRT, 7 who refused CCRT, 13 who received only radiotherapy, and 1 who received TMZ alone. Finally, 252 patients were included in the analysis.

The characteristics of the included patients are shown in Table 1. The median time from diagnosis to the start of CCRT was 20 days 4 to 6 (range, 8–47 days). The median therapeutic dose of radiation was 60 Gy (range, 7.2–84 Gy). The median follow-up period was 20.8 months, and 212 (84.1%) patients died during the study period. The median OS was 20.8 months (95% confidence interval [CI]: 17.7–23.9 months), and the median PFS was 12.7 months (95% CI: 11.2–14.2 months). The actuarial 1-, 3-, and 5-year OS rates were 79.8%, 28.2%, and 16.2%, respectively, and the actuarial 1-, 3-, and 5-year PFS rates were 54.1%, 14.4%, and 6.1%, respectively.

3.2. Clinical factors and prognostic relevance

The prognostic relevance of the clinical parameters is summarized in Table 2. As predicted, patients aged <50 years showed better prognosis than those aged ≥50 years. OS was significantly shorter in patients having lesions located in eloquent areas or with SVZ involvement, subependymal enhancement, or leptomeningeal dissemination. Using 3.4 cm as the cutoff-value, tumor size was unrelated to either OS and PFS. A Karnofsky performance status (KPS) score ≥80 was associated with improved OS, but not PFS.

At initial operation, 126 (50.0%), 55 (21.8%), 45 (17.9%), and 26 (10.3%) patients underwent GTR, STR, PR, and biopsy, respectively. Both OS and PFS were higher in subjects who underwent GTR than in those who underwent STR, PR, and biopsy. Median OS was 27.9 months (95% CI, 22.8–32.9 months) in patients who underwent GTR, but there were no differences in OS or PFS among patients who underwent STR, PR, and biopsy (Fig. 1). Patients who underwent GTR had 1-, 3-, and 5-year OS rates of 91.3%, 38.6%, and 25.3%, respectively, whereas patients who underwent incomplete resection (STR, PR, and biopsy) had 1-, 3-, and 5-year OS rates of 68.0%, 17.6%, and 7.2%, respectively.

MGMT promoter methylation was detected in 78/229 (34.1%) patients and was associated with superior PFS and OS. MGMT status was not determined in 23 patients due to insufficient amount of tissue. Most of these patients (18/23) were who had undergone biopsy alone. IDH1 mutations were found in 7/106 (6.6%) patients. The median OS for patients with mutated and wild-type IDH1 were 67.1 and 21.1 months, respectively ($P = .138$). Ki67 labeling index was not associated with PFS or OS. Patients with GCGBMs did not differ from those with GBM in either PFS or OS, whereas patients with GBMO showed significantly longer PFS and OS than other patients.

Table 1

Patient characteristics.

Age, y	57 (19.0–82.0)
Sex	
Female	131 (52.0)
Male	121 (48.0)
Location	
Left	101 (40.1)
Right	123 (48.8)
Bilateral	22 (8.7)
Central	6 (2.4)
Size, cm, mean ± SD	4.65 ± 1.55
KPS (median)	
Preoperative	70
Postoperative	70
MGMT promoter status (n = 229)	
Methylated	78 (34.0)
Unmethylated	151 (66.0)
IDH1 mutation (n = 106)	
Yes	99 (93.4)
No	7 (6.6)
Pathology	
Glioblastoma	213 (84.5)
GCGBM	10 (4.0)
GBMO	29 (11.5)
Early discontinuation of CCRT	4 (1.6)
Adjuvant temozolomide	
0	22 (8.7)
1–3	41 (16.3)
4–6	141 (56.0)
7+	48 (19.0)

Values are presented as number (%) or median (range) unless otherwise indicated. CCRT = concomitant chemoradiotherapy, IDH = isocitrate dehydrogenase, KPS = Karnofsky performance status, MGMT = O⁶-methylguanine-DNA methyltransferase.

3.3. Multivariate analysis for outcome

Univariate analyses showed that factors significantly prognostic of OS and PFS included patient age, KPS, EOR, MGMT promoter methylation status, eloquent area involvement, SVZ involvement, and leptomeningeal seeding. In performing multivariate logistic regression analysis, patients with missing values were excluded; therefore, multivariate analysis included only the 229 patients with known MGMT promoter methylation status. Young age (<50 years), GTR, subependymal enhancement on preoperative MRI, and MGMT promoter methylation were found to be independently prognostic factors for both PFS and OS (Table 3), whereas eloquent area involvement and leptomeningeal dissemination were significantly prognostic only for OS.

3.4. Overall survival related to 3 significant prognostic factors

Treatment outcome was analyzed in 8 groups of patients stratified by the 3 most significant prognostic factors; age, MGMT promoter methylation, and EOR (Table 4). The median OS of the 13 patients with methylated MGMT, young age (<50 years), and GTR was 67.1 months (range, 12.7–121.5 months). In contrast, the median OS of the 45 patients with an unmethylated MGMT gene, older age (≥50 years), and less than STR was 14.8 months.

4. Discussion

Clinical factors considered significantly prognostic for survival in patients with GBM include age, performance status, EOR, tumor

Table 2

Univariate analyses of factors prognostic for OS and PFS.

Variable	N	PFS, mo Median (95% CI)	P	OS, mo Median (95% CI)	P
All patients	252	12.7 (11.2–14.2)		20.8 (17.7–23.9)	
Age group					
Younger (<50 y)	75	15.0 (12.5–17.5)		28.8 (22.3–35.3)	
Older (≥50 y)	177	11.5 (10.2–12.8)	.025	17.5 (14.6–20.4)	.003
Eloquent area involvement					
Noneloquent	89	14.7 (10.9–18.5)		24.7 (20.9–28.5)	
Near-eloquent	40	12.7 (9.2–16.2)	.067	18.5 (14.6–22.4)	.058
Eloquent	123	11.3 (10.0–12.6)	.013	18.1 (13.9–22.3)	.002
Subventricular zone involvement					
No involvement	106	14.4 (11.1–17.7)		24.2 (18.5–29.9)	
Touching ventricle	146	11.2 (8.6–13.8)	.006	18.1 (14.9–21.3)	.032
Leptomeningeal seeding					
No	207	13.6 (12.2–15.0)		22.5 (19.6–25.4)	
Subependymal enhancement	33	7.2 (3.9–10.5)	<.001	14.9 (13.7–16.1)	<.001
Cortical enhancement	6	5.8 (2.9–8.7)	.153	8.2 (1.6–14.8)	.657
Definite Seeding	6	6.1 (0.2–12.0)	.040	7.0 (0.2–13.8)	<.001
Maximum diameter					
<3.4 cm	51	16.9 (10.9–22.9)		30.2 (18.6–41.8)	
≥3.4 cm	201	12.3 (10.9–13.7)	.062	18.3 (15.7–20.9)	.097
Preoperative KPS (%)					
≥80	111	13.1 (11.0–15.2)		23.5 (17.4–29.6)	
<80	141	12.3 (10.5–14.1)	.394	18.3 (14.7–21.9)	.023
Extent of resection					
Total resection	126	16.4 (13.7–19.1)		27.9 (22.8–32.9)	
Subtotal resection	55	9.0 (6.0–12.0)	<.001	15.8 (12.7–18.9)	<.001
Partial resection	45	9.1 (4.1–14.0)	.001	15.5 (12.5–18.5)	.003
Biopsy	26	8.3 (4.5–12.1)	<.001	17.2 (12.1–22.3)	.005
MGMT promoter methylation (n=229)					
Yes	78	19.6 (12.3–26.9)		33.2 (25.8–40.6)	
No	151	11.8 (10.2–13.4)	<.001	17.4 (14.4–20.4)	<.001
IDH1 mutation (n=106)					
Yes	7	29.1 (0.0–62.2)		67.1 (0.0–146.7)	
No	99	13.1 (11.8–14.4)	.073	21.1 (15.1–27.1)	.138
Ki67 labeling index (n=117)					
<20.0	58	12.0 (10.1–13.9)		21.5 (14.6–28.4)	
≥20.0	59	14.1 (13.0–15.2)	.721	23.5 (15.0–32.0)	.787
Pathology					
GBM	213	12.1 (10.7–13.5)		19.4 (16.3–22.5)	
GCGBM	10	10.2 (0.0–30.6)	.197	26.7 (0.0–75.7)	.149
GBMO	29	17.1 (7.1–27.1)	.003	28.8 (16.1–41.5)	.013

CI = confidence interval, CSF = cerebrospinal fluid, GBM = glioblastoma, GBMO = glioblastoma with oligodendroglioma component, GCGBM = giant cell glioblastoma, IDH = isocitrate dehydrogenase, KPS = Karnofsky performance status, MGMT = O^6-methylguanine-DNA methyltransferase, OS = overall survival, PFS = progression-free survival, SVZ = subventricular zone.

Figure 1. Kaplan–Meier analysis of the effects of extent of resection on progression-free survival (PFS) (A) and overall survival (B). Total resection significantly benefited PFS and overall survival when compared with subtotal resection, partial resection, and biopsy ($P < .001$ each).

Table 3

Multivariate analyses of factors prognostic for OS and PFS.

	Progression		Death	
	Relative risk (95% CI)	P	Relative risk (95% CI)	P
Younger age (<50 y)	0.64 (0.47–0.88)	.006	0.57 (0.41–0.78)	.001
Eloquent area				
Eloquent area involvement	1.25 (0.90–1.76)	.187	1.71 (1.22–2.41)	.002
Near-eloquent area involvement	1.13 (0.74–1.75)	.570	1.46 (0.94–2.26)	.092
Leptomeningeal seeding				
Subependymal enhancement	1.87 (1.21–2.90)	.005	1.92 (1.24–2.99)	.004
Cortical enhancement	2.24 (0.90–5.56)	.082	0.80 (0.29–2.21)	.671
Disseminated	1.72 (0.73–4.07)	.216	4.12 (1.73–9.82)	.001
Gross total resection	0.48 (0.35–0.65)	<.001	0.60 (0.44–0.81)	.001
MGMT promoter methylation	0.56 (0.41–0.76)	<.001	0.58 (0.43–0.80)	.001

CI = confidence interval, MGMT = O^6-methylguanine-DNA methyltransferase.

Table 4

Relationships among 3 factors significant prognostic of OS.

Age group	MGMT promoter methylation status	EOR	N	Median OS	P
<50	Methylated	GTR	13	67.1 (12.7–121.5)	.014
		STR + PR + biopsy	7	36.6 (27.8–45.4)	
	Unmethylated	GTR	21	37.2 (17.5–56.9)	.006
		STR + PR + biopsy	30	15.9 (8.4–23.4)	
≥50	Methylated	GTR	38	32.8 (24.6–41.0)	.213
		STR + PR + biopsy	20	17.5 (11.8–23.2)	
	Unmethylated	GTR	55	16.9 (11.7–22.1)	.005
		STR + PR + biopsy	45	14.8 (13.2–16.4)	

CI = confidence interval, EOR = extent of resection, GTR = gross total resection, MGMT = O^6-methylguanine-DNA methyltransferase, OS = overall survival, PR = partial resection, STR = subtotal resection.

location, degree of necrosis, and enhancement on preoperative MRI.[6] Because the treatment modality influences the survival rate, we analyzed only those patients who agreed to start standard therapy (CCRT plus TMZ). The median OS of GBM patients who underwent TMZ-based CCRT reported in large prospective studies is shown in Table 5.

The median OS and PFS of all patients in this study were 20.8 and 12.7 months, much higher than the 14.6 and 6.9 months reported in the EORTC/NCIC study.[1] One plausible cause for this discrepancy may have been the higher percentage of patients in our study who underwent total resection. In our study, 50% of subjects underwent GTR, with a median OS of 27.9 months, significantly higher than the median OS of the patients who

underwent STR, PR, and biopsy. In the EORTC/NCIC study, approximately 40% of patients underwent GTR; however, that report provided limited information regarding the method used to select patients for GTR. In our study, the criteria for GTR were thoroughly assessed through intraoperative findings and postoperative MRI within 48 hours. In addition, we performed so-called supratotal resection when tumors were confined in noneloquent areas, removing as much of the brain as possible from adjacent tumors unless they affect function.[18] A future study will assess the survival benefits of supratotal resection.

Salvage treatment after recurrence could also have contributed to longer OS. Of the 217 patients with recurrent GBM, 44 underwent a second operation, 4 underwent a third operation,

Table 5

Literature findings of patient characteristics, PFS, OS, and EOR in patients with GBM.

Author	Year	Study region	No. of patients	No. of GTR	PFS	OS	OS of GTR group
Stupp et al[1]	2005	Europe*	287	113 (39.4)	6.9	14.6	18.8
Lai et al[3]	2011	USA	110	47 (42.7)	7.6	21.1	–
Oike et al[27]	2013	Japan	45	7 (15.6)	–	15.8	–
Kreth et al[28]	2013	Germany	222	92 (41.4)	7.8	17.1	21
Yang et al[11]	2013	China	226	102 (45.1)	8.8	14.4	–
Chinot et al[29]	2014	Europe†	463	196 (42.3)	6.2	16.7	–
Gilbert et al[30]	2014	USA‡	309		7.3	16.1	–
Grabowski et al[31]	2014	USA	128	57 (44.5)	–	13.8	19
This study	2016	Korea	252	126 (50.0)	12.7	20.8	27.9

Values are presented as number (%) or median months unless otherwise indicated. GTR = gross total resection, OS = overall survival, PFS = progression-free survival, STR = subtotal resection.
* EORTC-NCIC, The European Organization for Research and Treatment of Cancer/National Cancer Institute of Canada.
† AVAGlio, The Avastin in Glioblastoma.
‡ RTOG, Radiation Therapy Oncology Group.

and 1 underwent a fourth operation for recurrent lesions. In addition, 21 patients underwent repeat radiation treatment or gamma knife surgery for recurrent lesions, and 48 were administered more than 6 cycles of adjuvant TMZ, with the latter treated with a median of 11 cycles (range, 7–24 cycles). Eight patients were treated with bevacizumab plus irinotecan for recurrent lesions. Studies are needed to analyze the effects of salvage treatments in patients with recurrent GBM.

Our results also confirmed that EOR is one of the most significant independent prognostic factors for both PFS and OS.[5,19–22] This factor is important, as it is the only prognostic factor adjustable by surgeons.

Several studies have reported that patients with GBMO have a better prognosis than those with GBM, and that GBMO is associated with a 1p/19q co-deletion.[23] In contrast, other studies have reported no correlation between GBMO and 1p/19q co-deletion or survival.[24] We observed differences in PFS and OS between patients with GBMO and those with GBM. The updated WHO classification in 2016 eliminated the category of GBMO, with these tumors now classified as GBM or anaplastic oligodendroglioma according to the IDH mutation and 1p/19q co-deletion. However, the patients in the present study were diagnosed before the WHO classification was updated, and 15% of patients the EORTC_26981/NCIC_CE.3 trial had GBMO.[24]

IDH mutation is an important genetic marker in gliomas. IDH-mutant GBMs are known to show much better prognosis than IDH-wildtype GBMs.[10] According to the WHO classification of tumors of the central nervous system published in 2016, GBM with IDH mutation is classified as a different entity from GBM with IDH-wildtype.[25] In our study, IDH mutation was examined in 42% of patients who performed immunohistochemical staining for IDH1 R132H. It is rare that adult GBM has mutations other than IDH1 R132H.[26] Even if some of the untested younger patients have IDH mutations, there is little chance of causing a significant change in the median survival. Among the examined patients, 6.6% had IDH mutation on the immunohistochemistry, similar to what is known in other studies. In addition, the other studies about GBM before WHO 2016 classification also included IDH-mutant GBM in survival analysis.

We also confirmed that MGMT promoter methylation is an independent prognostic factor of survival in patients with GBM.[9,12] Both PFS and OS were significantly higher in patients with MGMT methylation compared to those without such methylation. TMZ has been shown to enhance survival benefits in patients receiving CCRT, a finding supported in our study, in that most completed CCRT when TMZ was also administered.

The present study had several limitations, including its retrospective design, which may introduce selection bias. Four patients with newly diagnosed GBM were not eligible to start CCRT due to pneumonia. Thirteen patients, most of older age, received radiotherapy alone without TMZ. These patients were excluded from the analysis. However, the characteristics of patients in this study, including median age, age distribution, and performance status, were similar to those of patients in previous studies, such as the EORTC/NCIC trial, who received CCRT. Therefore, this limitation was not considered to have affected our comparison of OS.

5. Conclusion

The survival rate in patients with GBM is improved with surgery followed by CCRT plus TMZ. We also confirmed that age, MGMT promoter methylation status, tumor extent, and EOR are significant prognostic factors for survival in GBM patients. Further, we found that EOR was the only modifiable prognostic factor, suggesting that maximum safe resection can improve overall outcome in patients with GBM.

References

[1] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.

[2] Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66.

[3] Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011;29:142–8.

[4] Jafri NF, Clarke JL, Weinberg V, et al. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol 2013;15:91–6.

[5] Hardesty DA, Sanai N. The value of glioma extent of resection in the modern neurosurgical era. Front Neurol 2012;3:140.

[6] Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95:190–8.

[7] Lawrence YR, Mishra MV, Werner-Wasik M, et al. Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer 2012;118:4228–34.

[8] Koshy M, Villano JL, Dolecek TA, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 2012;107:207–12.

[9] Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.

[10] Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707–18.

[11] Yang H, Wei D, Yang K, et al. The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analysis. Neurochem Res 2014;39:2277–87.

[12] Kim YS, Kim SH, Cho J, et al. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys 2012;84:661–7.

[13] Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109.

[14] Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 1999;30:253–70.

[15] Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72.

[16] Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350–4.

[17] Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hyper-methylation is a common event in primary human neoplasia. Cancer Res 1999;59:793–7.

[18] Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the left dominant hemisphere: toward a "supratotal" resection. Clinical article. J Neurosurg 2011;115:232–9.

[19] Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg 2012;117:851–9.

[20] Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115:3–8.

[21] Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62:753–64. discussion 264–6.

[22] Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008;62:564–76. discussion 564–76.

[23] Vordermark D, Ruprecht K, Rieckmann P, et al. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer 2006;6:247.

[24] Hegi ME, Janzer RC, Lambiv WL, et al. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathol 2012;123:841–52.

[25] Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20.

[26] Yan H, Parsons D, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73.

[27] Oike T, Suzuki Y, Sugawara K, et al. Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PLoS One 2013;8:e78943.

[28] Kreth FW, Thon N, Simon M, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol 2013;24:3117–23.

[29] Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709–22.

[30] Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699–708.

[31] Grabowski MM, Recinos PF, Nowacki AS, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 2014;121:1115–23.